SCHEMBL10266347

SCHEMBL10266347

COC(=O)CN(C)C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 4/20 0.39
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
TET2 Q6N021 1/20 0.34
CA12 O43570 2/20 0.34
CA2 P00918 2/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
RIPK1 Q13546 1/20 0.34
RECQL P46063 1/20 0.33
NOTUM Q6P988 1/20 0.33
HSD11B1 P28845 1/20 0.31
KDM5A P29375 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5510748 0.80 MEN1 (0.34) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL12788588 0.79 CA12 (0.58) MEN1KMT2AKDM4EHSD17B10MGAM
SCHEMBL10260469 0.79 MGAM (0.34) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL3084209 0.75 KDM4E (0.43) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL7023795 0.75 CA14 (0.39) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL24339742 0.75 POLB (0.41) MEN1KMT2ATSHRKDM4EHSD17B10
SCHEMBL2909351 0.75 MGAM (0.46) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL27488643 0.75 TSHR (0.43) MEN1KMT2ATSHRKDM4EHTT
SCHEMBL13223497 0.75 RIPK1 (0.37) MEN1KMT2ATSHRKDM4ERIPK1
SCHEMBL19091682 0.75 RIPK1 (0.37) MEN1KMT2ARIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 US disclosed
US-20220098214-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS YALE UNIVERSITY 2022-03-31 US disclosed
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. 2012-08-16 US disclosed
US-8178681-B2 methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency SHIONOGI & CO., LTD. (JP) 2012-05-15 US disclosed
EP-1806342-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT MEN1 980/4885KMT2A 2016/4885TSHR 4780/4885
US-20120208813-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVES CNR2, CNR1, HRH4 MEN1 4298/4885KMT2A 2255/4885TSHR 1412/4885
US-20220098214-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS DUSP5, DUSP4, DUSP6 MEN1 4048/4885KMT2A 2227/4885TSHR 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.